Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Current Liabilities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Total Current Liabilities for 7 consecutive years, with $96.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 46.76% to $96.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $96.9 million, a 46.76% decrease, with the full-year FY2025 number at $96.9 million, down 46.76% from a year prior.
  • Total Current Liabilities was $96.9 million for Q4 2025 at Beam Therapeutics, down from $182.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $238.9 million in Q3 2022 to a low of $96.9 million in Q4 2025.
  • A 5-year average of $180.1 million and a median of $184.9 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 230.46% in 2021, then crashed 46.76% in 2025.
  • Beam Therapeutics' Total Current Liabilities stood at $213.4 million in 2021, then grew by 4.76% to $223.6 million in 2022, then dropped by 8.06% to $205.6 million in 2023, then fell by 11.43% to $182.1 million in 2024, then plummeted by 46.76% to $96.9 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Total Current Liabilities are $96.9 million (Q4 2025), $182.6 million (Q3 2025), and $174.1 million (Q2 2025).